This site uses cookies to bring you the best experience. Find out more
Skip to main content
↑

News

Find Out The Latest

Keep in touch with exciting developments from The Oxford Science Park and its occupiers here.

Contact us on comms@oxfordsp.com if you would like to know more about any of these stories.

You can also follow us on LinkedIn  

Cytox welcomes FDA’s approval of Biogen’s Aduhelm (aducanumab) to treat Alzheimer’s disease

Cytox welcomes FDA’s approval of Biogen’s Aduhelm (aducanumab) to treat Alzheimer’s disease

08 Jun 2021

Cytox welcomes FDA’s approval of Biogen’s Aduhelm (aducanumab) to treat Alzheimer’s disease Cytox genoSCORE-LAB test can identify patients most at risk of cognitive decline, and potentially most likely to benefit from new drug 8th June 2021: Oxford and Manchester, UK. Cytox Ltd, which provides non-invasive, risk assessment and patient stratification tools for Alzheimer’s disease (AD) and dementia, welcomes the decision from the US FDA... Read more

Oxular appoints Dr. Friedrich Asmus as CMO

Oxular appoints Dr. Friedrich Asmus as CMO

07 Jun 2021

Dr. Asmus brings two decades of experience leading global clinical and translational research programs for both retinal and rare diseases. OXFORD, UK, 7 June 2021 – Oxular Limited (“Oxular”), a leading retinal therapeutics development company, today announces it has appointed Dr. Friedrich (Fritz) Asmus as Chief Medical Officer. Dr. Asmus will lead all medical, clinical, and regulatory functions to... Read more

MoA Technology moves to The Oxford Science Park

MoA Technology moves to The Oxford Science Park

21 May 2021

MoA Technology has moved to the Bellhouse Building, a prestigious new facility recently opened at The Oxford Science Park. The first of more than 100 Oxford Sciences Innovation companies focused on cutting-edge technologies re-located to the Science Park in 2018.  More than 3,500 people work there across areas including immunology, artificial intelligence and systems biology. The Bellhouse Building is the most recently completed of three... Read more

Exscientia announces multi-target, AI-driven drug discovery collaboration with Bristol Myers Squibb

Exscientia announces multi-target, AI-driven drug discovery collaboration with Bristol Myers Squibb

19 May 2021

Upfront and potential milestones of over $1.2bn in addition to tiered royalties Exscientia, the clinical stage, Artificial Intelligence (AI)-driven pharmatech company, announced today that it has entered into a collaboration agreement with Bristol-Myers Squibb Company (NYSE: BMY).  This expanded collaboration has the potential to add to the Bristol Myers Squibb drug pipeline whilst enhancing Exscientia’s portfolio of shared assets. The... Read more

Exscientia Receives Queen’s Award for Enterprise in Innovation

Exscientia Receives Queen’s Award for Enterprise in Innovation

29 Apr 2021

Exscientia, a clinical-stage Artificial Intelligence (AI)-driven pharmatech company, today announced that it has won the Queen’s Award for Enterprise in Innovation, recognising its pioneering work in the field of AI-driven drug discovery. Her Majesty the Queen has acknowledged the success of Exscientia’s AI-driven drug discovery platform, repeatedly taking new molecules from discovery to the clinic with unprecedented efficiency and with... Read more

The Daubeny Project

Imaginative design, inspiring spaces.

450,000 sq ft of
premium lab space
completing 2026

Discover More